Company profile: Tavotek Biotherapeutics
1.1 - Company Overview
Company description
- Provider of therapeutic medicine discovery, development and commercialization, with platforms and programs including TavoSelect phage display to discover diversified human antibody sequences for biologics and diagnostics; TavoPrecise to develop optimized mono- and multi-specific biologics; TavoELITE to address intracellular undruggable targets; and oncology and immunology therapeutics for cancer, inflammatory and allergic diseases.
Products and services
- Oncology Therapeutics: Architects custom-engineered treatments for diverse cancers using multi-specific antibodies and protein engineering to modulate signaling pathways, emphasizing precise pathway targeting and optimized efficacy
- TavoPrecise: Engineers a modular platform to develop monoclonal and multi-specific biologics with optimized potency, specificity, and pharmacokinetics, enabling tailored therapeutic profiles across disease indications
- TavoELITE: Creates a cell-penetrating approach to target intracellular, historically undruggable targets in cancer and other diseases, featuring enhanced cell-specific internalization and efficient endosomal escape
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tavotek Biotherapeutics
Embark Veterinary
HQ: United States
Website
- Description: Provider of dog DNA testing to end preventable diseases in dogs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embark Veterinary company profile →
BridgeBio Pharma
HQ: United States
Website
- Description: Provider of precision medicines for genetic diseases and cancers, developing assets including BBP-398 (SHP2 inhibitor for MAPK/RAS-driven cancers), BBP-631 (AAV5 gene therapy for congenital adrenal hyperplasia), BBP-818 (AAV gene therapy for classic galactosemia), BBP-589 (recombinant collagen 7 for dystrophic epidermolysis bullosa), BBP-681 (topical PI3KA inhibitor), and BBP-711 (GO inhibitor).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BridgeBio Pharma company profile →
Hendrix Genetics
HQ: The Netherlands
Website
- Description: Provider of animal genetic solutions and breeding programs for laying hens, turkeys, traditional poultry, swine, salmon, shrimp, and trout. Develops sustainable standards to improve animal performance, food safety, animal welfare, and environmental protection, addressing contemporary challenges in the animal protein sector. Headquartered in Boxmeer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hendrix Genetics company profile →
Gnubio
HQ: United States
Website
- Description: Provider of scalable desktop DNA sequencing systems for diagnostic and applied markets, integrating target selection, DNA amplification, sequencing, and analysis via emulsion-based droplet microfluidics. Offers single-use consumable cartridges and workflows for targeted sequencing and hotspot analysis, with whole genome and transcriptome applications in development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gnubio company profile →
Genomatix
HQ: Germany
Website
- Description: Provider of computational biology software, databases, and services for understanding gene regulation at the molecular level, including sequence analysis, functional promoter analysis, proprietary genome annotation, and promoter sequence databases, plus testing and interpreting genomic data, representing a central part of systems biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomatix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tavotek Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tavotek Biotherapeutics
2.2 - Growth funds investing in similar companies to Tavotek Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tavotek Biotherapeutics
4.2 - Public trading comparable groups for Tavotek Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →